



**COGNIGENICS**

*Improving human cognition*

**Company Overview**



## Customer Need

Five million Americans with Alzheimer's disease need a way to maintain mental acuity and defend against cognitive decline.



# Solution


Cognigenics will produce an innovative treatment for relieving Alzheimer's symptoms which sharpens clarity, focus and mental acuity, while alleviating stress, depression and anxiety.






# Market

The worldwide cost of Alzheimer's care will reach \$1 trillion in 2020. A new treatment without side effects could restore quality of life for millions of patients and their families.



# Method

Our treatment promotes the production of alpha and theta frequency brainwaves, which are experimentally correlated with relaxation and cognitive ability.



# Competitive Advantage

- Current symptomatic relievers for Alzheimer's disease have low efficacy and carry side effects which can pose significant health issues for patients.
- Cognigenics gene therapies will bring patients into a relaxed and lucid state without side effects.





# Management Team



Dean Radin, PhD

Pioneering  
consciousness  
researcher

A I S



Barry Linder, MD

Experienced  
biotech  
entrepreneur

I S



John Mee

Experienced  
manufacturing  
executive

I



James Fallon, PhD

Distinguished  
neuroscientist

A I S



David Hitt

Experienced  
IP strategist




Troy Rohn, PhD

Neuroscience  
researcher

Key: A = Author I = Inventor S = Speaker




Extensibility



One Product

Patients: 80M  
No side effects

## Cognigenics Platform Technology



– Disorder-specific clinical applications –



# Roadmap



# Conclusions

- Cognitive gene therapies can raise quality of life for millions of Alzheimer's patients and their families
  - Lowering society's overall cost for elder care
- Cognigenics' platform technology is extensible to serve a market of 80 million people affected by a wide spectrum of cognitive issues



# Contact

## Cognigenics, LLC

1390 N. McDowell Blvd., Suite G317

Petaluma, California 94954 USA

Voice: 1-772-324-8800

Web: [cognigenics.co](http://cognigenics.co)

Email: [office@cognigenics.co](mailto:office@cognigenics.co)

